Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
1,713,253 | 1,824,834 | 1,704,578 | 1,597,663 | 1,538,826 |
Cost of Goods Sold (COGS) incl. D&A |
948,066 | 979,647 | 992,358 | 926,135 | 886,636 |
COGS excluding D&A |
825,580 | 806,485 | 867,223 | 800,314 | 778,599 |
Depreciation & Amortization Expense |
122,486 | 173,162 | 125,135 | 125,821 | 108,037 |
Gross Income |
765,187 | 845,187 | 712,220 | 671,528 | 652,190 |
SG&A Expense |
480,121 | 450,662 | 453,577 | 417,728 | 377,104 |
Research & Development |
117,771 | 108,250 | 94,361 | 80,959 | 76,077 |
Other SG&A |
362,350 | 342,412 | 359,216 | 336,769 | 301,027 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
22,878 | 47,686 | -3,283 | -6,235 | 38,141 |
Non Operating Income/Expense |
5,774 | -3,411 | 6,389 | -16,658 | -27,150 |
Equity in Affiliates (Pretax) |
NA | NA | 0 | NA | NA |
Interest Expense |
76,934 | 78,627 | 78,336 | 85,106 | 80,919 |
Gross Interest Expense |
76,934 | 78,627 | 78,336 | 85,106 | 80,919 |
Pretax Income |
191,028 | 264,801 | 189,979 | 158,271 | 128,876 |
Income Tax |
28,696 | 52,762 | 50,843 | 28,844 | -1,018 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
162,332 | 212,039 | 139,136 | 129,427 | 129,894 |
Minority Interest Expense |
368 | 782 | 586 | 348 | 403 |
Net Income |
161,964 | 211,257 | 138,550 | 129,079 | 129,491 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
161,964 | 211,256 | 138,550 | 129,079 | 129,491 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
161,964 | 211,257 | 138,550 | 129,079 | 129,491 |
Operational EPS |
0.42 | 0.59 | 0.32 | 0.29 | 0.36 |
EPS (basic) |
0.40 | 0.52 | 0.33 | 0.30 | 0.30 |
EBITDA |
407,552 | 567,687 | 383,778 | 379,621 | 383,123 |
Depreciation & Amortization Expense |
122,486 | 173,162 | 125,135 | 125,821 | 108,037 |
Common Shares Outstanding |
420,236 | 411,562 | 424,394 | 432,365 | 438,785 |
Basic Shares Outstanding |
415,210 | 406,469 | 420,281 | 427,251 | 430,839 |
Diluted Shares Outstanding |
420,236 | 411,562 | 424,394 | 432,365 | 438,785 |
Diluted EPS after Extraordinary Items |
0.39 | 0.51 | 0.33 | 0.30 | 0.30 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.39 | 0.52 | 0.33 | 0.30 | 0.30 |
*Figures in thousands of U.S. Dollars except shares outstanding.
